Cargando…

Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome

Background: Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) Syndrome is a rare recessive disorder caused by mutations in the FOXP3 gene. In addition, there has been an increasing number of patients with wild-type FOXP3 gene and, in some cases, mutations in other immune regulat...

Descripción completa

Detalles Bibliográficos
Autores principales: Gambineri, Eleonora, Ciullini Mannurita, Sara, Hagin, David, Vignoli, Marina, Anover-Sombke, Stephanie, DeBoer, Stacey, Segundo, Gesmar R. S., Allenspach, Eric J., Favre, Claudio, Ochs, Hans D., Torgerson, Troy R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223101/
https://www.ncbi.nlm.nih.gov/pubmed/30443250
http://dx.doi.org/10.3389/fimmu.2018.02411
_version_ 1783369360192045056
author Gambineri, Eleonora
Ciullini Mannurita, Sara
Hagin, David
Vignoli, Marina
Anover-Sombke, Stephanie
DeBoer, Stacey
Segundo, Gesmar R. S.
Allenspach, Eric J.
Favre, Claudio
Ochs, Hans D.
Torgerson, Troy R.
author_facet Gambineri, Eleonora
Ciullini Mannurita, Sara
Hagin, David
Vignoli, Marina
Anover-Sombke, Stephanie
DeBoer, Stacey
Segundo, Gesmar R. S.
Allenspach, Eric J.
Favre, Claudio
Ochs, Hans D.
Torgerson, Troy R.
author_sort Gambineri, Eleonora
collection PubMed
description Background: Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) Syndrome is a rare recessive disorder caused by mutations in the FOXP3 gene. In addition, there has been an increasing number of patients with wild-type FOXP3 gene and, in some cases, mutations in other immune regulatory genes. Objective: To molecularly asses a cohort of 173 patients with the IPEX phenotype and to delineate the relationship between the clinical/immunologic phenotypes and the genotypes. Methods: We reviewed the clinical presentation and laboratory characteristics of each patient and compared clinical and laboratory data of FOXP3 mutation-positive (IPEX patients) with those from FOXP3 mutation-negative patients (IPEX-like). A total of 173 affected patients underwent direct sequence analysis of the FOXP3 gene while 85 IPEX-like patients with normal FOXP3 were investigated by a multiplex panel of “Primary Immune Deficiency (PID—related) genes.” Results: Forty-four distinct FOXP3 variants were identified in 88 IPEX patients, 9 of which were not previously reported. Among the 85 IPEX-like patients, 19 different disease-associated variants affecting 9 distinct genes were identified. Conclusions: We provide a comprehensive analysis of the clinical features and molecular bases of IPEX and IPEX-like patients. Although we were not able to identify major distinctive clinical features to differentiate IPEX from IPEX-like syndromes, we propose a simple flow-chart to effectively evaluate such patients and to focus on the most likely molecular diagnosis. Given the large number of potential candidate genes and overlapping phenotypes, selecting a panel of PID-related genes will facilitate a molecular diagnosis.
format Online
Article
Text
id pubmed-6223101
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-62231012018-11-15 Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome Gambineri, Eleonora Ciullini Mannurita, Sara Hagin, David Vignoli, Marina Anover-Sombke, Stephanie DeBoer, Stacey Segundo, Gesmar R. S. Allenspach, Eric J. Favre, Claudio Ochs, Hans D. Torgerson, Troy R. Front Immunol Immunology Background: Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) Syndrome is a rare recessive disorder caused by mutations in the FOXP3 gene. In addition, there has been an increasing number of patients with wild-type FOXP3 gene and, in some cases, mutations in other immune regulatory genes. Objective: To molecularly asses a cohort of 173 patients with the IPEX phenotype and to delineate the relationship between the clinical/immunologic phenotypes and the genotypes. Methods: We reviewed the clinical presentation and laboratory characteristics of each patient and compared clinical and laboratory data of FOXP3 mutation-positive (IPEX patients) with those from FOXP3 mutation-negative patients (IPEX-like). A total of 173 affected patients underwent direct sequence analysis of the FOXP3 gene while 85 IPEX-like patients with normal FOXP3 were investigated by a multiplex panel of “Primary Immune Deficiency (PID—related) genes.” Results: Forty-four distinct FOXP3 variants were identified in 88 IPEX patients, 9 of which were not previously reported. Among the 85 IPEX-like patients, 19 different disease-associated variants affecting 9 distinct genes were identified. Conclusions: We provide a comprehensive analysis of the clinical features and molecular bases of IPEX and IPEX-like patients. Although we were not able to identify major distinctive clinical features to differentiate IPEX from IPEX-like syndromes, we propose a simple flow-chart to effectively evaluate such patients and to focus on the most likely molecular diagnosis. Given the large number of potential candidate genes and overlapping phenotypes, selecting a panel of PID-related genes will facilitate a molecular diagnosis. Frontiers Media S.A. 2018-11-01 /pmc/articles/PMC6223101/ /pubmed/30443250 http://dx.doi.org/10.3389/fimmu.2018.02411 Text en Copyright © 2018 Gambineri, Ciullini Mannurita, Hagin, Vignoli, Anover-Sombke, DeBoer, Segundo, Allenspach, Favre, Ochs and Torgerson. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Gambineri, Eleonora
Ciullini Mannurita, Sara
Hagin, David
Vignoli, Marina
Anover-Sombke, Stephanie
DeBoer, Stacey
Segundo, Gesmar R. S.
Allenspach, Eric J.
Favre, Claudio
Ochs, Hans D.
Torgerson, Troy R.
Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome
title Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome
title_full Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome
title_fullStr Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome
title_full_unstemmed Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome
title_short Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome
title_sort clinical, immunological, and molecular heterogeneity of 173 patients with the phenotype of immune dysregulation, polyendocrinopathy, enteropathy, x-linked (ipex) syndrome
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223101/
https://www.ncbi.nlm.nih.gov/pubmed/30443250
http://dx.doi.org/10.3389/fimmu.2018.02411
work_keys_str_mv AT gambinerieleonora clinicalimmunologicalandmolecularheterogeneityof173patientswiththephenotypeofimmunedysregulationpolyendocrinopathyenteropathyxlinkedipexsyndrome
AT ciullinimannuritasara clinicalimmunologicalandmolecularheterogeneityof173patientswiththephenotypeofimmunedysregulationpolyendocrinopathyenteropathyxlinkedipexsyndrome
AT hagindavid clinicalimmunologicalandmolecularheterogeneityof173patientswiththephenotypeofimmunedysregulationpolyendocrinopathyenteropathyxlinkedipexsyndrome
AT vignolimarina clinicalimmunologicalandmolecularheterogeneityof173patientswiththephenotypeofimmunedysregulationpolyendocrinopathyenteropathyxlinkedipexsyndrome
AT anoversombkestephanie clinicalimmunologicalandmolecularheterogeneityof173patientswiththephenotypeofimmunedysregulationpolyendocrinopathyenteropathyxlinkedipexsyndrome
AT deboerstacey clinicalimmunologicalandmolecularheterogeneityof173patientswiththephenotypeofimmunedysregulationpolyendocrinopathyenteropathyxlinkedipexsyndrome
AT segundogesmarrs clinicalimmunologicalandmolecularheterogeneityof173patientswiththephenotypeofimmunedysregulationpolyendocrinopathyenteropathyxlinkedipexsyndrome
AT allenspachericj clinicalimmunologicalandmolecularheterogeneityof173patientswiththephenotypeofimmunedysregulationpolyendocrinopathyenteropathyxlinkedipexsyndrome
AT favreclaudio clinicalimmunologicalandmolecularheterogeneityof173patientswiththephenotypeofimmunedysregulationpolyendocrinopathyenteropathyxlinkedipexsyndrome
AT ochshansd clinicalimmunologicalandmolecularheterogeneityof173patientswiththephenotypeofimmunedysregulationpolyendocrinopathyenteropathyxlinkedipexsyndrome
AT torgersontroyr clinicalimmunologicalandmolecularheterogeneityof173patientswiththephenotypeofimmunedysregulationpolyendocrinopathyenteropathyxlinkedipexsyndrome